Stock AMGN AMGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2025-02-06 pm EST 		5-day change 1st Jan Change
297.78 USD -3.26% Intraday chart for Amgen Inc. +4.84% +14.25%
Feb. 06 Daiwa Securities Adjusts Amgen's Price Target to $350 From $360 MT
Feb. 06 Trump faces pressure from US industry over China tariff on medicines RE

Press Releases

Search
See the results
Amgen : Highlights from Amgen’s 2024 Fourth Quarter and Full Year Earnings Report
Feb. 04
 PU
Amgen: Q4 Earnings Snapshot
Feb. 04
 AQ
AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Feb. 03
 AQ
AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Jan. 31
 PR
Correction And Interpretation Of Errors In A Patent At The UPC
Jan. 30
 AQ
Amgen : North Carolina Ribbon Cutting Marks Important Milestone in Expansion to Meet Growing Demand for Amgen Medicines
Jan. 24
 PU
Amgen : Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products
Jan. 24
 PU
AMGEN - FDA APPROVES LUMAKRAS IN COMBINATION WITH VECTIBIX FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Jan. 20
 AQ
Amgen : Advancement in Combination Biomarker Driven Therapy for Adult Patients with Chemorefractory KRAS G12C Mutated Metastatic Colorectal Cancer (mCRC)
Jan. 17
 PU
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Jan. 17
 PR
Amgen : 43rd Annual JP Morgan Healthcare Conference Presentation
Jan. 13
 PU
AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Jan. 08
 PR
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
Jan. 07
 AQ
Amgen's Nobel Laureate Network: A Catalyst for Innovation
Dec. 11
 PU
AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND
Dec. 10
 PR
A Fight for Hope: Inspiring Others Through Childhood B-ALL
Dec. 06
 PU
AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA
Dec. 05
 PR
Update On Pending Denosumab BPCIA Litigations
Dec. 05
 AQ
AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE
Dec. 02
 PR
AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE
Dec. 02
 AQ
AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE
Nov. 29
 PR
AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY
Nov. 27
 AQ
Unexpected Results In Hatch Waxman Litigation: A Review Of Legal Decisions From 2023
Nov. 27
 AQ
Amgen : MariTide Topline Phase 2 Results
Nov. 26
 PU
AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM
Nov. 26
 PR
Become a member to access more news.
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. News Amgen Inc.
  5. Press Releases